- Associated Press - Friday, April 25, 2014

NEW YORK (AP) - Johnson & Johnson said Friday that European Union regulators approved a pill that combines its diabetes drug Invokana with metformin, an older treatment for the disease.

Janssen-Cilag International will market the drug under the name Vokanamet. It is intended to treat type 2 diabetes, in which the body does not use insulin efficiently.

The U.S. Food and Drug Administration approved Invokana in March 2013. European Union authorities followed suit in November.

Shares of Johnson & Johnson lost 19 cents to $99.77 in midday trading.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide